Literature DB >> 27837436

Withaferin A and its potential role in glioblastoma (GBM).

Jasdeep Dhami1, Edwin Chang2, Sanjiv S Gambhir3.   

Abstract

Within the Ayurvedic medical tradition of India, Ashwagandha (Withania somnifera) is a well-known herb. A large number of withanolides have been isolated from both its roots and its leaves and many have been assessed for their pharmacological activities. Amongst them, Withaferin A is one of its most bioactive phytoconstituents. Due to the lactonal steroid's potential to modulate multiple oncogenic pathways, Withaferin A has gained much attention as a possible anti-neoplastic agent. This review focuses on the use of Withaferin A alone, or in combination with other treatments, as a newer option for therapy against the most aggressive variant of brain tumors, Glioblastoma. We survey the various studies that delineate Withaferin A's anticancer mechanisms, its toxicity profiles, its pharmacokinetics and pharmacodynamics and its immuno-modulating properties.

Entities:  

Keywords:  Anticancer; Ashwagandha; Glioblastoma; Immunomodulation; Oncogenic pathways; Pharmacodynamics; Pharmacokinetics; Pharmacological; Withaferin A; Withania somnifera; Withanolides

Mesh:

Substances:

Year:  2016        PMID: 27837436     DOI: 10.1007/s11060-016-2303-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  69 in total

1.  Haemolytic anaemia and abdominal pain--a cause not to be missed.

Authors:  Martin Toniolo; Alessandro Ceschi; Marianne Meli; Andreas Lohri; Geneviève Favre
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

2.  Immunosuppressive activity of two plant steroidal lactones withaferin A and withanolide E.

Authors:  B Shohat; I Kirson; D Lavie
Journal:  Biomedicine       Date:  1978 Jan-Feb

3.  Immunomodulatory activity of Withania somnifera.

Authors:  L Davis; G Kuttan
Journal:  J Ethnopharmacol       Date:  2000-07       Impact factor: 4.360

4.  Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.

Authors:  Patrick T Grogan; Jann N Sarkaria; Barbara N Timmermann; Mark S Cohen
Journal:  Invest New Drugs       Date:  2014-04-10       Impact factor: 3.850

5.  Immunomodulatory role of Withania somnifera root powder on experimental induced inflammation: An in vivo and in vitro study.

Authors:  M Rasool; P Varalakshmi
Journal:  Vascul Pharmacol       Date:  2006-05-18       Impact factor: 5.773

6.  Withaferin A down-regulates lipopolysaccharide-induced cyclooxygenase-2 expression and PGE2 production through the inhibition of STAT1/3 activation in microglial cells.

Authors:  Kyoung-Jin Min; Kyounghwa Choi; Taeg Kyu Kwon
Journal:  Int Immunopharmacol       Date:  2011-03-21       Impact factor: 4.932

7.  Regulation of annexin A2 by reversible glutathionylation.

Authors:  Jennifer F Caplan; Nolan R Filipenko; Sandra L Fitzpatrick; David M Waisman
Journal:  J Biol Chem       Date:  2003-12-10       Impact factor: 5.157

8.  Immune modulation and apoptosis induction: Two sides of antitumoural activity of a standardised herbal formulation of Withania somnifera.

Authors:  Fayaz Malik; Ajay Kumar; Shashi Bhushan; Dilip M Mondhe; Harish C Pal; Rohit Sharma; Anamika Khajuria; Surjeet Singh; Gurdarshan Singh; Ajit K Saxena; Krishan A Suri; Ghulam N Qazi; Jaswant Singh
Journal:  Eur J Cancer       Date:  2009-03-05       Impact factor: 9.162

9.  In vivo growth inhibitory and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma.

Authors:  P U Devi; A C Sharada; F E Solomon
Journal:  Cancer Lett       Date:  1995-08-16       Impact factor: 8.679

10.  HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers.

Authors:  Marc L Mendillo; Sandro Santagata; Martina Koeva; George W Bell; Rong Hu; Rulla M Tamimi; Ernest Fraenkel; Tan A Ince; Luke Whitesell; Susan Lindquist
Journal:  Cell       Date:  2012-08-03       Impact factor: 41.582

View more
  7 in total

1.  Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields.

Authors:  Edwin Chang; Christoph Pohling; Nooshin Beygui; Chirag B Patel; Jarrett Rosenberg; Dong Ho Ha; Sanjiv S Gambhir
Journal:  J Neurooncol       Date:  2017-07-05       Impact factor: 4.130

2.  Differential Effects of Wedelia chinensis on Human Glioblastoma Multiforme Cells.

Authors:  Li-Jeng Chen; Tsai-Ching Hsu; Pei-Jung Yeh; Jia Le Yow; Chia-Ling Chang; Cheng-Hui Lin; Bor-Show Tzang
Journal:  Integr Cancer Ther       Date:  2021 Jan-Dec       Impact factor: 3.279

3.  Analysis of Stemness and Prognosis of Subtypes in Breast Cancer Using the Transcriptome Sequencing Data.

Authors:  Wei Chen; Zhipeng Hong; Shaohong Kang; Xinying Lv; Chuangui Song
Journal:  J Oncol       Date:  2022-03-09       Impact factor: 4.375

Review 4.  The Role of Natural Products as Inhibitors of JAK/STAT Signaling Pathways in Glioblastoma Treatment.

Authors:  Hanieh Fahmideh; Hooriyeh Shapourian; Rasol Moltafeti; Chanour Tavakol; Razieh Forghaniesfidvajani; Hamidreza Zalpoor; Mohsen Nabi-Afjadi
Journal:  Oxid Med Cell Longev       Date:  2022-09-19       Impact factor: 7.310

5.  Withaferin A inhibits proliferation of human endometrial cancer cells via transforming growth factor-β (TGF-β) signalling.

Authors:  Kejun Xu; Hongyan Shi; Yongming Du; Jilan Ou
Journal:  3 Biotech       Date:  2021-06-10       Impact factor: 2.893

6.  CDC7-dependent transcriptional regulation of RAD54L is essential for tumorigenicity and radio-resistance of glioblastoma.

Authors:  Qi Li; Wanfu Xie; Ning Wang; Chuankun Li; Maode Wang
Journal:  Transl Oncol       Date:  2018-02-04       Impact factor: 4.243

7.  Integrative Analysis of a Novel Eleven-Small Nucleolar RNA Prognostic Signature in Patients With Lower Grade Glioma.

Authors:  Teng Deng; Yizhen Gong; Xiwen Liao; Xiangkun Wang; Xin Zhou; Guangzhi Zhu; Ligen Mo
Journal:  Front Oncol       Date:  2021-06-07       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.